Takashi Owa Selected Research

5-chloroquinoxaline-2-sulfanilamide (chloroquinoxaline sulfonamide)

1/2017

Selective degradation of splicing factor CAPERα by anticancer sulfonamides.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Takashi Owa Research Topics

Disease

13	Neoplasms (Cancer) 01/2022 - 10/2002
2	Sarcoma (Soft Tissue Sarcoma) 07/2020 - 01/2018
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2019 - 01/2018
1	Colonic Neoplasms (Colon Cancer) 01/2022
1	Adenomatous Polyposis Coli (Familial Adenomatous Polyposis) 01/2021
1	Hypoxia (Hypoxemia) 01/2021
1	Stomach Neoplasms (Stomach Cancer) 01/2021
1	Polyps 01/2021
1	Vascular System Injuries 07/2020
1	Fibrosarcoma 07/2020
1	Squamous Cell Carcinoma of Head and Neck 01/2020
1	Head and Neck Neoplasms (Head and Neck Cancer) 01/2020
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2018
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2018
1	Febrile Neutropenia 01/2018
1	Breast Neoplasms (Breast Cancer) 07/2009
1	Carcinoma (Carcinomatosis) 07/2009
1	Melanoma (Melanoma, Malignant) 10/2007
1	Colorectal Neoplasms (Colorectal Cancer) 11/2002

Drug/Important Bio-Agent (IBA)

6	SulfonamidesIBA 01/2017 - 10/2002
5	N- (3- chloro- 7- indolyl)- 1,4- benzenedisulphonamide (E7070)IBA 01/2018 - 01/2004
3	CateninsIBA 01/2022 - 01/2020
3	Pharmaceutical PreparationsIBA 01/2017 - 01/2004
2	CREB-Binding ProteinIBA 01/2022 - 01/2021
2	Antineoplastic Agents (Antineoplastics)IBA 01/2021 - 01/2004
2	N- (3- cyano- 4- methyl- 1H- indol- 7- yl)- 3- cyanobenzene- sulfonamideIBA 01/2017 - 11/2002
2	Antimitotic AgentsIBA 05/2006 - 10/2002
1	Biological ProductsIBA 01/2022
1	Immune Checkpoint InhibitorsIBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	Tyrosine Kinase InhibitorsIBA 07/2020
1	Immunoglobulin G (IgG)IBA 07/2020
1	Sphingomyelin Phosphodiesterase (Sphingomyelinase)IBA 07/2020
1	CeramidesIBA 07/2020
1	Angiogenesis InhibitorsIBA 07/2020
1	lenvatinibIBA 07/2020
1	AntimetabolitesIBA 07/2020
1	AcidsIBA 07/2020
1	Gemcitabine FDA Link 07/2020
1	ErbB Receptors (EGF Receptor)IBA 01/2020
1	RNA-Binding Proteins (RNA-Binding Protein)IBA 01/2019
1	ElectrolytesIBA 01/2018
1	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2018
1	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 01/2018
1	tazemetostatIBA 01/2018
1	5-chloroquinoxaline-2-sulfanilamide (chloroquinoxaline sulfonamide)IBA 01/2017
1	RNA Splicing FactorsIBA 01/2017
1	Estrogen ReceptorsIBA 01/2017
1	Irinotecan (Camptosar)FDA LinkGeneric 05/2012
1	EstersIBA 10/2009
1	jorunnamycin CIBA 10/2009
1	renieramycin MIBA 10/2009
1	BromidesIBA 07/2009
1	indoleIBA 05/2006
1	Carbonic Anhydrase InhibitorsIBA 01/2004
1	IsoenzymesIBA 01/2004
1	Growth InhibitorsIBA 06/2003
1	TubulinIBA 10/2002

Therapy/Procedure

3	Therapeutics 07/2020 - 10/2007
1	Drug Therapy (Chemotherapy) 07/2020
1	Radiotherapy 07/2020
1	Oral Administration 11/2002